However, expression of mutant IDH1 or IDH2 in concert with Jak2V617F resulted in the expansion of blasts and impaired hematopoietic differentiation, which are features of human MPN indicative of disease progression and adverse clinical outcome. Here, IDH1 is linked to myeloproliferative disorder.